




1 Supplementary figure 1

2




3

4

5


6 Supplementary figure 2

7






8
9

10 Supplementary figure 3
11




12
13
14







24 Supplementary figure 6
25






26
27

28 Supplementary figure 7
29



30
31





41 Supplementary table 1

42

Name	Primer/sgRNA sequences (5'-3')
<i>Wt1</i> ^{+/Ctg} -Forward	CTTCAGCTGTTCGGTGGCACAGTT
<i>Wt1</i> ^{+/Ctg} -Reverse	AGAAGCCAGGAGGCAGCAGAGAA
<i>Wt1</i> ^{+/Ctg} -sgRNA	CCGCGCGCCCCTGCGCAACG TGG
<i>Cre-ER</i> TM -Forward	CGA TGC AAC GAG TGA TGA GG
<i>Cre-ER</i> TM -Reverse	GCA TTG CTG TCA CTT GGT CGT
<i>Sfl-Cre</i> -Forward	TCCAATTTACTGACCGTACACCAA
<i>Sfl-Cre</i> -Reverse	CCTGTACCTGGCAATTTTCGGCTA
<i>Cyp17a1-Cre</i> - Forward	CCGCGCTGGAGTTTCAATAC
<i>Cyp17a1-Cre</i> - Reverse	TGGGTCTATAGAGGGAAAGATCAGG
<i>AMH-Cre</i> -Forward	TCCAATTTACTGACCGTACACCAA
<i>AMH-Cre</i> -Reverse	CCTGTACCTGGCAATTTTCGGCTA
<i>mT-mG</i> -Forward1	CTCTGCTGCCTCCTGGCTTCT
<i>mT-mG</i> -Reverse1	CGAGGCGGATCACAAGCAATA
<i>mT-mG</i> -Reverse2	TCAATGGGCGGGGGTCGTT

43

44

45

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
<i>Wt1-KTS</i>	CATACCAGTGTGACTTCAA GGACT	AGGGCTTTTCACCTGTATGA
<i>Hsd17b3</i>	ATGGCATCGGGAAAGCCTA T	CTCTTCTGCAATGGTCTGTA GC
<i>Fshr</i>	TGCTCTAACAGGGTCTTCCT C	TCTCAGTTCAATGGCGTTCC G
<i>Fgf9</i>	TGCAGGACTGGATTTCAATT AG	CCAGGCCCACTGCTATACTG
<i>Clu</i>	TGAAGGGCCAGTGTGAAAA GT	TGAACAGTCCACAGACAAG ATCTC
<i>Dmrt1</i>	GGAGTCTCCCAGCACCTTA CG	TCTGCCACTGGTTTCCAGTCT
<i>Sox9</i>	GCATCTGCACAACGCGG	AGCCTCCAGAGCTTGCCC
<i>Amh</i>	TGGTGCTAACCGTGGACTT C	AGCCAAATAGAAAGGCTTGC A
<i>Dhh</i>	GGACCTCGTACCCAACACTAC AA	CGATGGCTAGAGCGTTCACC
<i>ErbB4</i>	CAGCGCTTCTCAGTCAGTG T	CTGCTGTTCCAGGTCAGAGA
<i>Shbg</i>	CCAAAATCAGCAAACCCCA TT	CTGGATCCCAGGTTTCGAAAC
<i>Cyp26b1</i>	ACATCCACCGCAACAAGC	GGGCAGGTAGCTCTCAAGTG
<i>Foxl2</i>	ACAACACCGGAGAAACCAG AC	CGTAGAACGGGAACCTTGGCT A
<i>Rspo1</i>	CGACATGAACAAATGCATC A	CTCCTGACACTTGGTGCAGA
<i>Wnt4</i>	AGACGTGCGAGAAACTCAA AG	GGAACCTGGTATTGGCACTCC T
<i>Fst</i>	TGGATTAGCCTATGAGGGA AAG	TGGAATCCCATAGGCATTTT

<i>Bmp2</i>	GCTAGATCTGTACCGCAGG CACTCA	TCCCACATCTCTGGAAGT TCCTC
<i>Esr2</i>	TGTGCTATGGCCAACTTCTG	AGTAACAGGGCTGGCACAA C
<i>Cyp11a1</i>	CCAGTGTCCCCATGCTCAA C	TGCATGGTCCTTCCAGGTCT
<i>Cyp17a1</i>	GATCTAAGAAGCGCTCAGG CA	GGGCACTGCATCACGATAAA
<i>Hsd3b1</i>	CTCAGTTCTTAGGCTTCAGC AATTAC	CCAAAGGCAAGATATGATTT AGGA
<i>Star</i>	CCGGAGCAGAGTGGTGTCA	CAGTGGATGAAGCACCATGC
<i>Nr5a1</i>	AGGTGTCGGGCTACCACTA C	CCACCCCGCATTCGATCAG
<i>Lhr</i>	AATGAGTCCATCACGCTGA AAC	CCTGCAATTTGGTGGGAAGAG A
<i>EH</i>	GGACATCCACTTCATCCAC GT	AGCAAGGGCTTTGGAGTGC
<i>Gapdh</i>	GTCATTGAGAGCAATGCCA G	GTGTTGCTACCCCAATGTG

48
49
50

51 Supplementary table 3

52

Antibody name	Reference	Dilution	Source
SOX9	Ab5535	1:200	Millipore
FOXL2	ab246511	1:100	Abcam
WT1	ab89901	1:200	Abcam
CYP17A1	94004S	1:200	Cell signaling technology
3 β -HSD	sc30820	1:200	Santa Cruz
AMH	sc6886	1:200	Santa Cruz
GFP	ab13970	1:1000	Abcam
α -SMA	ab5694	1:200	Abcam
GAPDH	AF5009	1:1000	Beyotime

53

54

55

56 **Supplementary Fig 1. Generation of the *Wt1^{+Ctg}* mouse model.** **a** Schematic diagram of strategy
57 for generating *Wt1-KTS* knock-in mouse model. **b** The mRNA level of *Wt1-KTS* in *Wt1^{+Ctg}*;
58 *Cre-ERTM* MEFs was significantly increased after tamoxifen treatment ($n = 6$). **c** The protein level
59 of WT1 was dramatically increased in *Wt1^{+Ctg}*; *Cre-ERTM* MEFs after tamoxifen treatment. Tam,
60 tamoxifen. Data are presented as mean \pm SEM. * $P < 0.05$; ** $P < 0.01$.

61
62 **Supplementary Fig 2. The expression of *Wt1-KTS* was significantly increased in the testis of**
63 ***Wt1^{+Ctg}*; *Sfl1-Cre* mice at E12.5.** **a** The mRNA level of *Wt1-KTS* was significantly increased in
64 testes of *Wt1^{+Ctg}*; *Sfl1-Cre* mice at E12.5 compared to control testes ($n = 6$). **b-c** The protein level
65 of WT1 was significantly increased in *Wt1^{+Ctg}*; *Sfl1-Cre* testes ($n = 3$). Data are presented as mean
66 \pm SEM. * $P < 0.05$; ** $P < 0.01$.

67
68 **Supplementary Fig 3. FOXL2-positive granulosa-like cells were detected in the testis**
69 **interstitium of adult *Wt1^{+Ctg}*; *Sfl1-Cre* mice.** The seminiferous tubules were outlined by α -SMA
70 (Green). **a, c** 3β -HSD-positive Leydig cells (**a**, white arrows) were observed in control testes but
71 not in testes of *Wt1^{+Ctg}*; *Sfl1-Cre* mice (**c**). **b, d** A few FOXL2-positive cells were noted in the
72 interstitium of *Wt1^{+Ctg}*; *Sfl1-Cre* (**d**, white arrowheads) but not in control testes (**b**).

73
74 **Supplementary Fig 4. WT1-KTS protein was detected in Leydig cells of *Wt1^{+Ctg}*; *Cyp17a1-***
75 ***Cre* mice at E16.5.** *Wt1-KTS* was overexpressed in Leydig cells by crossing *Wt1^{+Ctg}*; *mT-mG*
76 mice with *Cyp17a1-Cre* mice. **c, f** The expression of GFP, WT1, and 3β -HSD in testes of *mT-mG*;
77 *Cyp17a1-Cre* and *Wt1^{+Ctg}*; *mT-mG*; *Cyp17a1-Cre* mice was examined by immunofluorescence.
78 GFP signal was detected in testes of *mT-mG*; *Cyp17a1-Cre* mice (**c**, yellow arrows) and

79 colocalized with 3 β -HSD, but no WT1 signal was detected in GFP-positive cells (**f**, white arrows).
80 **i** The expression of WT1 was expressed in not only Sertoli cells but also GFP-positive Leydig cells
81 in testes of *Wtl*^{+/*Ctg*}; *mT-mG*; *Cyp17a1-Cre* mice (white arrowheads).
82
83 **Supplementary Fig 5. Overexpression of *Wtl-KTS* induced Leydig cells to granulosa-like**
84 **cells transformation.** *Wtl-KTS* was overexpressed in Leydig cells by crossing *Wtl*^{+/*Ctg*}; *mT-mG*
85 mice with *Cyp17a1-Cre* mice. The expression of SOX9, GFP, 3 β -HSD, and FOXL2 in testes and
86 ovaries of *mT-mG*; *Cyp17a1-Cre* mice, and testes of *Wtl*^{+/*Ctg*}; *mT-mG*; *Cyp17a1-Cre* mice at
87 E16.5 was examined by immunofluorescence. **a, d, g** SOX9-positive cells (red, yellow arrows)
88 were detected in the testicular cords of *mT-mG*; *Cyp17a1-Cre* (**a**) and *Wtl*^{+/*Ctg*}; *mT-mG*; *Cyp17a1-*
89 *Cre* (**d**) mice but not in ovaries of *mT-mG*; *Cyp17a1-Cre* mice (**g**). **a, d, g** GFP signal was detected
90 in the testicular interstitium of *mT-mG*; *Cyp17a1-Cre* (**a**) and *Wtl*^{+/*Ctg*}; *mT-mG*; *Cyp17a1-Cre* (**d**)
91 mice but not in ovaries of *mT-mG*; *Cyp17a1-Cre* mice (**g**). 3 β -HSD (red) was expressed in testes
92 of *mT-mG*; *Cyp17a1-Cre* mice and colocalized with GFP (B, white arrows). **e** 3 β -HSD was also
93 detected in testes of *Wtl*^{+/*Ctg*}; *mT-mG*; *Cyp17a1-Cre* mice and colocalized with GFP (white
94 arrowheads), whereas the expressive level was significantly reduced. **c, i** large number of FOXL2-
95 positive cells (red) were noted in control ovaries (**i**, yellow arrowheads) but not in control testes
96 (**c**). **f** FOXL2 signal (yellow arrowheads) was detected in testes of *Wtl*^{+/*Ctg*}; *mT-mG*; *Cyp17a1-*
97 *Cre* mice and colocalized with GFP. **j** The mRNA level of Sertoli cell-specific genes, such as *Sox9*,
98 *Amh*, *Dhh*, and *Fgf9*, was not significantly changed in testes of *Wtl*^{+/*Ctg*}; *mT-mG*; *Cyp17a1-Cre*
99 mice, but steroidogenic cell-specific genes, such as *Cyp11a1*, *Star*, *Hsd3b1*, and *Cyp17a1* were
100 significantly decreased compared with control testes (*n* = 6). The mRNA level of *Foxl2* and *Rspo1*

101 was up-regulated in *Wtl*^{+/*Ctg*}; *Cyp17a1-Cre* testes, whereas *Fst* and *Wnt4* were not increased in
102 *Wtl*^{+/*Ctg*}; *Cyp17a1-Cre* teste (*n* = 6). Data are presented as mean ± SEM. **P* <0.05; ***P* <0.01.

103

104 **Supplementary Fig 6. FOXL2-positive cells were observed in the testes of adult *Wtl*^{+/*Ctg*};**
105 ***Cyp17a1-Cre* mice. a, c** The seminiferous tubules were outlined by α-SMA (Green). 3β-HSD-
106 positive Leydig cells were observed in the interstitium of control testes (**a**) but not in *Wtl*^{+/*Ctg*}; *mT-*
107 *mG*; *Cyp17a1-Cre* testis (**c**). **b, d** No GFP and FOXL2 double-positive cells were noted in control
108 testes (**b**, white arrows), but several GFP and FOXL2 double-positive cells were observed in
109 *Wtl*^{+/*Ctg*}; *mT-mG*; *Cyp17a1-Cre* testes (**d**, yellow arrows).

110

111 **Supplementary Fig 7. Overexpression of *Wtl-KTS* in Sertoli cells using *AMH-Cre* transgenic**
112 **mice. a-c** Co-expression of GFP (**a**, green) and Sertoli cell marker AMH (**b**, red) in E14.5 *mT-mG*;
113 *Sfl-Cre* gonads (**c**, white arrows). **d** The mRNA level of *Wtl-KTS* was significantly up-regulated
114 in *Wtl*^{+/*Ctg*}; *AMH-Cre* compared to that level measured in control testes (*n* = 6). Data are presented
115 as mean ± SEM. **P* <0.05; ***P* <0.01.

116

117 **Supplementary Fig 8. No FOXL2-positive cell was detected in the testis of *Wtl*^{+/*Ctg*}; *AMH-***
118 ***Cre* mice at E16.5. *Wtl-KTS* was overexpressed in Sertoli cells by crossing *Wtl*^{+/*Ctg*}; *mT-mG***
119 **mice with *AMH-Cre* mice. a, d, g** The expression of SOX9, 3β-HSD, α-SMA, and FOXL2 in
120 control testes, control ovaries, and testes of *Wtl*^{+/*Ctg*}; *AMH-Cre* mice at E16.5 were examined by
121 immunofluorescence. SOX9-positive Sertoli cells (red, yellow arrows) were observed in testicular
122 cords of control (**a**) and *Wtl*^{+/*Ctg*}; *AMH-Cre* mice (**d**) but not in control ovaries (**g**). **b, e, h** 3β-
123 HSD-positive Leydig cells (red, white arrows) were observed in the testes of control (**b**) and

124 *Wt1^{+/-Ctg}; AMH-Cre* mice (**e**) but not in control ovaries (**h**). **c, f, i** FOXL2-positive granulosa cells
125 (red, white arrowheads) were observed in control ovaries (**i**) but not in control testes (**c**) and
126 *Wt1^{+/-Ctg}; AMH-Cre* testes (**f**). **j** The mRNA levels of Sertoli cell-specific genes, steroidogenic cell-
127 specific genes, and granulosa cell-specific genes were examined by RT-PCR ($n = 6$). Data are
128 presented as mean \pm SEM. * $P < 0.05$; ** $P < 0.01$.

129

130 **Supplementary Fig 9. No feminized characteristics were detected in *Wt1^{+/-Ctg}; AMH-Cre* mice**
131 **at 2 weeks of age.** The seminiferous tubules and follicles were outlined by α -SMA (Green). **a, d,**
132 **g** SOX9-positive Sertoli cells were normally located in seminiferous tubules in both control (**a**)
133 and *Wt1^{+/-Ctg}; AMH-Cre* (**d**) testes and no signal was observed in control ovaries (**g**). **b, e, h**
134 Numerous FOXL2-positive granulosa cells were detected in control ovaries (**h**) but not in control
135 (**b**) and *Wt1^{+/-Ctg}; AMH-Cre* (**e**) testes. **c, f, i** 3 β -HSD protein was detected in the interstitium in
136 control testes (**c**), *Wt1^{+/-Ctg}; AMH-Cre* (**f**) testes, and control ovaries (**i**).

137

138 **Supplementary table 1. List of primers of PCR and sgRNA sequences.**

139

140 **Supplementary table 2. List of primers used for real-time PCR to assess the relative mRNA**
141 **level of target genes.**

142

143 **Supplementary table 3. List of antibodies.**

144

145

146 **Supplementary materials and methods**

147 **Mice**

148 All animal experiments were conducted following the protocols approved by the Institutional
149 Animal Care and Use Committee of the Institute of Zoology, Chinese Academy of Sciences (CAS;
150 SYXK 2018-0021). All mice were derived from a C57/ICR mixed background and housed under
151 specific pathogen-free (SPF) laboratory conditions. *Wt1^{+Ctg}* mice were mated with mice carrying
152 the *Cre-ERTM* (14), *Sfl-Cre*^{1,2}, *Cyp17a1-Cre*, *AMH-Cre*³, and *mT-mG* transgenic⁴ mice to generate
153 *Wt1^{+Ctg}; Cre-ERTM*, *Wt1^{+Ctg}; Sfl-Cre*, *Wt1^{+Ctg}; mT-mG*, *Cyp17a1-Cre*, and *Wt1^{+Ctg}; mT-mG*;
154 *AMH-Cre* mice. Detailed information on the generation of the *Wt1^{+Ctg}* knock-in (KI) mouse model
155 was provided in Supplementary Fig. S1. The mice were genotyped using DNA isolated from tail
156 biopsies through polymerase chain reaction (PCR) and Sanger sequencing. The specific primers
157 used for PCR are listed in Supplemental table S1.

158

159 **Histological analysis**

160 Tissues were initially fixed in 4% paraformaldehyde (PFA) for 18–24 hours (h) and transferred to
161 70% ethanol. Following fixation, the samples were embedded in paraffin, and 5- μ m sections were
162 cut and then mounted on glass slides. After deparaffinization and rehydration, the sections were
163 processed with hematoxylin and eosin (H&E) staining. Images were captured with a Nikon Digital
164 sight (DS)-Ri1 charge-coupled device (CCD) camera.

165

166 **Immunohistochemistry (IHC) analysis**

167 IHC was performed as described previously⁵. Briefly, tissues were fixed in 4% paraformaldehyde
168 (PFA) for 18–24 hours (h) and then transferred to 70% ethanol. Fixed samples were embedded in

169 paraffin, and 5- μ m sections were cut and then mounted on glass slides. After deparaffinization and
170 rehydration, the sections were processed with IHC staining. IHC staining was conducted using a
171 Vectastain ABC (avidin-biotin-peroxidase) kit (Vector Laboratories, Burlingame, CA) as
172 recommended. The stained sections were examined using Nikon Microscopy, and images were
173 captured with a Nikon DS-Ri1 CCD camera.

174

175 **Immunofluorescence (IF) analysis**

176 Gonads samples were fixed, embedded, sectioned, deparaffinized, and rehydrated as described for
177 IHC. After antigen retrieval, the sections were incubated with 0.3% Triton X-100 for 10 minutes
178 for antigen retrieval and incubated with blocking buffer (BSA, 5% w/v) for 1 hr at room
179 temperature (RT). Subsequently, the sections were incubated with the diluted primary antibodies.
180 After washing three times with phosphate-buffered saline (PBS), the sections were incubated with
181 corresponding Fluorescein isothiocyanate (FITC), CyTM3, and Tetramethylrhodamine
182 Isothiocyanate (TRITC)-conjugated second antibodies (Jackson ImmunoResearch) and 4, 6-
183 diamidino-2-phenylindole (DAPI) for 1 hr at RT (room temperature). Finally, images were
184 captured with a Zeiss LSM 880 confocal microscope (Carl Zeiss Inc, Thornwood, NY). The
185 fluorescence intensity of the DNA methylation signal was quantified by using Fiji ImageJ software.

186

187 **Real-time PCR (RT-PCR) analysis**

188 Total RNA was isolated from gonads using a RNeasy Kit (Aidlab, RN28) according to the
189 manufacturer-recommended protocol. The total RNA concentration was measured using a
190 NanoDrop 2000 (Thermo Fisher Scientific). Subsequently, 2 μ g of total RNA was used to
191 synthesize the first-strand cDNA (Abm, G592). Diluted cDNAs were analyzed by RT-PCR using

192 SYBR Green I Mastermix (Abm, MasterMix-S) with a LightCycler 480 system (Roche).
193 Amplification was performed: denaturation steps at 95 °C for 10 minutes, 40 cycles of 95 °C for
194 15 seconds, and 60 °C for 1 minute. All gene expression was normalized to *Gapdh*. The relative
195 target gene expression levels were calculated using the formula $2^{-\Delta\Delta CT}$ and specific primers
196 (Supplementary table S2).

197

198 **Western blot analysis**

199 For mouse embryonic fibroblast (MEF) and testes, total protein was harvested with RIPA Lysis
200 Buffer (Applygen, P1053) supplemented with Complete Mini Protease Inhibitor Cocktail Tablets
201 (Roche Applied Science, 04693116001) and 1 mM Phenylmethanesulfonyl fluoride (PMSF). The
202 homogenates or cell lysates were centrifuged at $13,000 \times g$ for 15 minutes at 4 °C to remove debris,
203 and the protein concentration in the supernatant was determined using the Bio-Rad protein assay
204 kit (Bio-Rad). Equal amounts of protein lysates (approximately 25 µg) were separated by sodium
205 dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto
206 nitrocellulose membranes. The membranes were blocked with 5% skim milk following transfer to
207 prevent non-specific binding. The membranes were then incubated overnight at 4 °C with the
208 following primary antibody. After thorough washing, the membranes were incubated with
209 secondary antibodies for 1 hour at room temperature. The immunoreactive bands were visualized
210 and detected using the ODYSSEY Sa Infrared Imaging System (LI-COR Biosciences, Lincoln,
211 NE). GAPDH was used as a reference control and that quantitation was performed by normalizing
212 WT1 protein expression levels to those of GAPDH. The antibodies used are listed in Supplemental
213 table S3.

214

215 **Statistical analysis**

216 All experiments were repeated three times, including at least three independent biological samples.
217 Quantitative data are presented as mean \pm SEM. A *p*-value < 0.05 was considered statistically
218 significant using an unpaired two-tailed Student' s t-test. Analysis was performed using Prism
219 version 8.0.1 (GraphPad Software).

220

221 **References**

- 222 1. Bingham, N. C. et al. *Genesis* **44**, 419-424 (2006).
223 2. Huang, C. C., Yao, H. H. *BMC Dev Biol* **10**, 66 (2010).
224 3. Lécureuil, C. et al. *Genesis* **33**, 114-118 (2002).
225 4. Muzumdar, M. D. et al. *Genesis* **45**, 593-605 (2007).
226 5. Gao, F. et al. *Proc Natl Acad Sci U S A* **103**, 11987-11992 (2006).